✅ Model Answer:
• Diagnosis: Sickle cell nephropathy causing nephrogenic diabetes insipidus — medullary damage and papillary necrosis impair urine concentrating ability. Hypernatremia (146 mEq/L), dilute urine (180 mOsm/kg), no DDAVP response (urine osm 190 → 200, <50% rise). Normal glucose excludes DM. History of sickle cell disease (HbSS) is the key clue. Enuresis is a common manifestation of polyuria in SCD.
• Any other test: Renal function (creatinine, BUN), urinalysis (microalbuminuria, proteinuria), renal ultrasound (papillary necrosis, medullary echogenicity), HbS percentage, hydroxyurea levels.
• What to do next: Optimize sickle cell disease management (hydroxyurea, hydration, prevent crises). Avoid NSAIDs. For NDI: thiazide diuretic + amiloride to reduce urine output. Ensure adequate free water access.
• Follow-up plan: Monitor renal function, urine output, blood pressure. Screen for chronic kidney disease. Regular hematology and nephrology follow-up.

✅ Model Answer:
• Pathophysiology: Sickling of red blood cells in the renal medulla causes several changes:
- Medullary ischemia: Sickling in the vasa recta → reduced blood flow to the renal medulla → ischemia and infarction.
- Papillary necrosis: Ischemia of the renal papillae → necrosis and sloughing → impaired concentrating ability.
- Loss of medullary hypertonicity: Damage to the loop of Henle and collecting ducts → reduced sodium and urea gradient → impaired water reabsorption.
- Decreased aquaporin-2 (AQP2) expression: Collecting duct dysfunction → ADH resistance.
- Chronic kidney disease: Progressive interstitial fibrosis and glomerulosclerosis.
• Progression: NDI can be an early manifestation of sickle cell nephropathy, often preceding overt proteinuria or renal failure.

✅ Model Answer:
• Early manifestations:
- Concentrating defect: Nephrogenic DI (most common early renal manifestation).
- Enuresis: Due to polyuria and nocturnal urine production.
- Hematuria: Microscopic or macroscopic (due to papillary necrosis).
- Hyposthenuria: Inability to concentrate urine (urine osmolality <400 mOsm/kg).
• Progressive manifestations:
- Microalbuminuria: Earliest sign of glomerular damage.
- Proteinuria: Progressive glomerulopathy → nephrotic syndrome.
- Chronic kidney disease (CKD): Declining GFR → end-stage renal disease (ESRD) in 10-15% of patients with HbSS.
- Hypertension: Due to renal dysfunction and hypervolemia.
- Papillary necrosis: Sloughing of renal papillae → gross hematuria, flank pain.
- Renal medullary carcinoma: Rare but aggressive malignancy.

✅ Model Answer:
• Hydroxyurea: A disease-modifying therapy for sickle cell disease.
• Mechanism: Increases fetal hemoglobin (HbF) production → reduces sickling and hemolysis.
• Benefits for renal function:
- Reduces vaso-occlusive crises: Decreases sickling in the renal medulla.
- Decreases microalbuminuria: Reduces glomerular damage.
- Slows progression of CKD: Preserves renal function over time.
- Reduces episodes of papillary necrosis.
• Dosing: 15-35 mg/kg/day (adjusted to maximum tolerated dose).
• Monitoring: CBC, HbF levels, renal function.
• Indications: All children with HbSS ≥9 months of age with recurrent vaso-occlusive crises, acute chest syndrome, or severe anemia.

✅ Model Answer:
• Optimize SCD therapy:
- Hydroxyurea: First-line to reduce sickling and prevent further renal damage.
- Adequate hydration: Maintain good hydration to prevent sickling and reduce urine concentration.
- Avoid dehydration: Especially during illness or hot weather.
• Pharmacological therapy for NDI:
- Thiazide diuretic (hydrochlorothiazide): 1-2 mg/kg/day — paradoxically reduces urine output by inducing mild hypovolemia.
- Amiloride: 0.3-0.5 mg/kg/day — added if potassium-wasting is a concern.
- Low-sodium diet: Reduces urine volume.
- Indomethacin: 2 mg/kg/day — may be used in severe cases (monitor renal function).
• Monitor: Serum sodium, potassium, renal function, blood pressure.
• Avoid: NSAIDs (can worsen renal function), dehydration, nephrotoxic drugs.

✅ Model Answer:
• Complications:
- Chronic kidney disease (CKD): 10-15% of patients with HbSS develop ESRD.
- Nephrogenic DI: Polyuria, polydipsia, enuresis, dehydration.
- Papillary necrosis: Can cause gross hematuria, flank pain, and urinary obstruction.
- Hypertension: Due to renal dysfunction and hypervolemia.
- Proteinuria: Progressive glomerulopathy → nephrotic syndrome.
- Renal medullary carcinoma: Rare but aggressive malignancy (associated with HbSS and HbSC).
- Pregnancy complications: Increased risk of pre-eclampsia, worsening renal function.
- Death: ESRD is a significant cause of mortality in adults with SCD.

✅ Model Answer:
• Renal ultrasound: Important for evaluating structural complications of sickle cell nephropathy.
• Findings:
- Papillary necrosis: Irregular, echogenic papillae, or medullary cavities.
- Increased cortical echogenicity: Due to chronic fibrosis.
- Renal size: May be enlarged initially, then small with chronic disease.
- Renal stones: Due to hyperuricosuria and hypercalciuria.
- Hydronephrosis: If papillary necrosis causes obstruction.
- Renal cysts: Can occur.
• Indications:
- All children with sickle cell disease and renal symptoms (polyuria, hematuria, hypertension).
- If papillary necrosis is suspected.
- If renal function is declining.
• Follow-up: Repeat ultrasound if symptoms worsen or renal function declines.

✅ Model Answer:
• Prognosis:
- Variable: Depends on the severity of sickle cell disease and compliance with hydroxyurea and hydration.
- NDI: May be managed with thiazides and hydration; usually does not progress to ESRD on its own.
- Proteinuria: Can be reduced with ACE inhibitors and hydroxyurea.
- ESRD: Occurs in 10-15% of patients with HbSS (usually by the 3rd-4th decade).
- Hydroxyurea: Delays progression of renal disease.
- Life expectancy: Reduced in patients with ESRD; early detection and management improve outcomes.
• Long-term follow-up:
- Monitor: Renal function (creatinine, BUN), urine protein/creatinine ratio, blood pressure.
- Nephrology: Annual or bi-annual follow-up.
- Hematology: Optimize sickle cell disease management (hydroxyurea, transfusions).
- Avoid: NSAIDs, dehydration, and nephrotoxic drugs.
- Education: Teach patient and family about the importance of hydration, recognition of enuresis/polyuria, and medication adherence.